Selank®, an anxiolytic peptide pharmaceutical, has emerged as a promising therapeutic option with its unique combination of anxiolytic, antidepressant, and anti-asthenic attributes. Developed through a progressive journey starting with the discovery of anxiolytic potential in 1995, Selank exhibits a multifaceted pharmacological prow­ess. Selank’s potential therapeutic benefits extend to memory enhancement and cognitive functions, making it a promising candidate for improving learning and retention. Its role in protecting the immune system and reducing in­flammation in depression further highlights its versatility in addressing anxiety-asthenic disorders.